While sommarutide is undoubtedly an exciting potential treatment option, there is still a lack of clear clinical data on the mechanism of action of GLP-1 agonists in NASH, such as whether GLP-1 agonists have a direct, independent role in improving NASH, or simply by improving body weight, insulin resistance, and so on
Taking it along with diet and exercise helps control blood sugar levels
Long-term data from diabetes trials (SUSTAIN-6, spanning 2.4 years) revealed no unexpected safety signals in organ function, cardiovascular markers, or metabolic parameters during extended treatment
GLP-1R .38,39,40 GLP-1R (KO)
Some groups experienced extremely high rates of vomiting (up to 92%) when on the initial starting doses, which were full-strength doses right away